Evogene (NASDAQ:EVGN) Now Covered by StockNews.com

Analysts at StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a report issued on Thursday. The firm set a “sell” rating on the biotechnology company’s stock.

Evogene Stock Performance

Shares of EVGN stock opened at $1.46 on Thursday. Evogene has a one year low of $1.20 and a one year high of $10.40. The company’s 50-day moving average is $1.57 and its 200 day moving average is $2.50. The company has a market capitalization of $7.84 million, a price-to-earnings ratio of -0.33 and a beta of 1.29.

Evogene (NASDAQ:EVGN) last announced its quarterly earnings data on Thursday, November 21st. The biotechnology company reported ($1.31) EPS for the quarter. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%.

Institutional Trading of Evogene

A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC purchased a new stake in shares of Evogene Ltd. (NASDAQ:EVGN) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Hedge funds and other institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.